A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Trial details
- Registry ID
- NCT06682806
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 MutationNCT06682806 | Prelude Therapeutics Incorporated | Phase 2 | Terminated | 2026-01-23Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |